1. Home
  2. IMCR vs VVX Comparison

IMCR vs VVX Comparison

Compare IMCR & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • VVX
  • Stock Information
  • Founded
  • IMCR 2008
  • VVX 2014
  • Country
  • IMCR United Kingdom
  • VVX United States
  • Employees
  • IMCR N/A
  • VVX N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • VVX Diversified Commercial Services
  • Sector
  • IMCR Health Care
  • VVX Consumer Discretionary
  • Exchange
  • IMCR Nasdaq
  • VVX Nasdaq
  • Market Cap
  • IMCR 1.4B
  • VVX 1.5B
  • IPO Year
  • IMCR 2021
  • VVX 2014
  • Fundamental
  • Price
  • IMCR $29.58
  • VVX $49.56
  • Analyst Decision
  • IMCR Buy
  • VVX Buy
  • Analyst Count
  • IMCR 12
  • VVX 8
  • Target Price
  • IMCR $63.00
  • VVX $65.38
  • AVG Volume (30 Days)
  • IMCR 372.8K
  • VVX 324.8K
  • Earning Date
  • IMCR 05-07-2025
  • VVX 05-06-2025
  • Dividend Yield
  • IMCR N/A
  • VVX N/A
  • EPS Growth
  • IMCR N/A
  • VVX N/A
  • EPS
  • IMCR N/A
  • VVX 1.08
  • Revenue
  • IMCR $310,202,000.00
  • VVX $4,322,155,000.00
  • Revenue This Year
  • IMCR $18.97
  • VVX $4.44
  • Revenue Next Year
  • IMCR $8.43
  • VVX $4.61
  • P/E Ratio
  • IMCR N/A
  • VVX $45.88
  • Revenue Growth
  • IMCR 24.36
  • VVX 9.06
  • 52 Week Low
  • IMCR $27.19
  • VVX $41.08
  • 52 Week High
  • IMCR $66.00
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 49.95
  • VVX 51.54
  • Support Level
  • IMCR $28.92
  • VVX $49.12
  • Resistance Level
  • IMCR $30.04
  • VVX $52.58
  • Average True Range (ATR)
  • IMCR 1.49
  • VVX 1.93
  • MACD
  • IMCR 0.10
  • VVX 0.18
  • Stochastic Oscillator
  • IMCR 53.71
  • VVX 48.99

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: